Newswise — ANN ARBOR, Mich. — Twist and hold your neck to the left. Now down, and over to the right, until it hurts. Now imagine your neck – or arms or legs – randomly doing that on their own, without you controlling it.
Just like people with the neurological condition dystonia, this mouse's limbs twist and extend uncontrollably -- allowing researchers to study the disease's causes and potential treatment.
That’s a taste of what children and adults with a neurological condition called dystonia live with every day – uncontrollable twisting and stiffening of neck and limb muscles.
The mystery of why this happens, and what can prevent or treat it, has long puzzled doctors, who have struggled to help their suffering dystonia patients. Now, with support from The Bachmann-Strauss Dystonia & Parkinson Foundation’s 2013 Impact Grant, new research from a University of Michigan Medical School team may finally open the door to answering those questions and developing new options for patients.
In a new paper in the Journal of Clinical Investigation, the researchers describe new strains of mice they’ve developed that almost perfectly mimic a human form of the disease. They also detail new discoveries about the basic biology of dystonia, made from studying the mice.
They’ll soon make the mice available for researchers everywhere to study, to accelerate understanding of all forms of dystonia and the search for better treatments. The lack of such mice has held back research on dystonia for years.
The U-M team’s success in creating a mouse model for the disease came only after 17 years of stubborn, persistent effort – often in the face of setbacks and failure.
Led by U-M neurologist William Dauer, M.D., the team tried to figure out how and why a gene defect leads to an inherited form of dystonia that, intriguingly, doesn’t start until the pre-teen or teen years, after which it progresses for many years but then stops getting worse after the person reaches their mid-20s.
The gene defect responsible, called DYT1, causes brain cells to make a less-active form of a protein called torsinA. But despite more than a decade of effort by Dauer’s team and many others around the world, no one has been able to translate this information into an animal model with dystonia's characteristic movements.
Using the childhood onset as a clue, Dauer and his team used cutting-edge genetic technology to severely impair torsinA function during early brain development. This novel twist caused the new mice to closely mimic the human disease: they don’t develop dystonia until they reach preteen age in “mouse years,” and their symptoms stop getting worse after a while.
With this powerful tool in hand, Dauer’s team were now able to peer into the brains of these animals to begin to unravel the mysteries of the disease.
In an unexpected development, they found that the lack of torsinA in the brains of dystonic mice led to the death of neurons – a process called neurodegeneration – in just a few highly localized parts of the brain that control movement. Like the dystonic movements, this neurodegeneration began in young mice, progressed for a time, and then became fixed.
“We’ve created a model for understanding why certain parts of the brain are more vulnerable to problems from a certain genetic insult," says Dauer, an associate professor in the U-M departments of Neurology and Cell & Developmental Biology.
“In this case, we’re showing that in dystonia, the lack of this particular protein during a critical window of time is causing cell death. Every disease is telling us something about biology -- one just has to listen carefully.”
More discoveries to come
Dauer and his team don’t yet know why only one-third of human DYT1 gene mutation carriers develop primary dystonia during their school years, and why those who don’t develop the disease before their early 20s will never go on to develop it.
They believe some critical events during the brain’s development in infancy and childhood may have to do with it - and they’re already working to explore that question in mice.
They also believe their mouse model will help them and other researchers understand how dystonia occurs in people who have Parkinson’s disease, Huntington’s disease, or damage caused by a stroke or brain injury. Some people develop dystonia without either a known gene defect or any of these other diagnoses – a condition called idiopathic dystonia.
In all these cases, as in people with DYT1 mutations, dystonia’s twisting and curling motions likely arise from problems in the area of the brain that controls the body’s motor control system.
In other words, something’s going wrong in the process of sending signals to the nerves that control muscles involved in movement. Studying a “pure” form of dystonia using the mice will allow researchers to understand just what’s going on.
The team’s ultimate goal is to find new treatments for all kinds of dystonia. Currently, children, teens and young adults who develop it can take medications or even opt for a form of neurosurgery called deep brain stimulation. But the drugs carry major side effects and are only partially effective – and brain surgery carries its own risks. Dauer and his team are working to screen drug candidates.
In addition to Dauer, the research team included first author Chun-Chi Liang, and laboratory members Lauren M. Tanabe, Stephanie Jou, and Frank Chi.
The Bachmann-Strauss Dystonia & Parkinson Foundation
The Bachmann-Strauss Foundation is an independent, nonprofit, 501©(3) organization that was established in 1995 by Louis Bachmann (1916-2000) and Bonnie Strauss to find better treatments and cures for the movement disorders dystonia and Parkinson’s disease and to provide medical and patient information. The Foundation funds scientific and clinical research and helps raise awareness of dystonia and Parkinson’s disease among the general public and the medical community.
Since its founding, The Bachmann-Strauss Dystonia & Parkinson Foundation has given more than $17 million to support basic, translational and clinical research and other scientific and educational projects. Of this amount, the Foundation has invested $15 million in seed funding for 235 research grants, enabling researchers to leverage an additional $117 million from the National Institutes of Health and other sources. Additionally, the Foundation established four Bachmann-Strauss Dystonia and Parkinson’s Disease Centers of Excellence at leading medical research centers and institutes across the United States, to provide patients with specialized clinical care and access to cutting-edge research. The Centers are located at Mount Sinai Beth Israel Medical Center; the University of Alabama at Birmingham; the University of California, San Francisco; and the University of Florida. Major accomplishments of the Foundation include funding the discovery of dystonia genes, the creation of animal models, and the advancement of new therapies and treatments (drugs and deep brain stimulation).
For further information about The Bachmann-Strauss Dystonia & Parkinson Foundation, visit the Foundation’s web site at www.dystonia-parkinson.org.
Patients interested in learning more about dystonia care at the U-M Health System should visit http://www.uofmhealth.org/medical-services/dystonia.
Funding: The research was funded by The Bachmann-Strauss Dystonia and Parkinson Disease Foundation, a Fellowship from the Dystonia Medical Research Foundation (to L.M. Tanabe), the Robert P. Apkarian Integrated Electron Microscopy Core of Emory University, and a grant from the National Institute of Neurological Disorders and Stroke, NS077730.
Reference: Journal of Clinical Investigation, Volume 124 Number 7, July 2014 doi:10.1172/JCI72830
This press release is adapted from a University of Michigan Health System article.